How do you define a rare cancer? This is one the most commonly asked questions we receive- and the answer isn’t a simple one. While the default factor cited...
A New Rare Cancer Partnership
read more
Research & Innovation
Looking Back at 2016
As 2016 draws to a close, we are proud to look back on an outstanding year of new programs and research success for TargetCancer Foundation. In 2016...
Our Largest Round of Grants to Date
We are proud to announce our largest round of rare cancer grant funding to date: $200,000 in new grants supporting innovative rare cancer research, as well as...
An Amazing 2015
Our sixth year was TargetCancer Foundation's best ever, as we saw unprecedented growth and research success. We are gearing up for an even bigger 2016, but in...
Fostering Esophageal Cancer Progress
In 2012, we identified a need for a scientific meeting uniting key players in cholangiocarcinoma research. In order to best foster collaboration and informal...
Casual Beginnings for an Innovative Collaboration
Great coverage of TargetCancer Foundation's support of an innovative esophageal cancer collaboration at the Dana-Farber Cancer Institute. What started as a...
Giving New Hope to Patients
"When the late Paul Poth was diagnosed with a form of cancer so rare there was no treatment, he helped to launch a highly promising area of cancer research...
Renewed Commitment. New Hope.
In 2009, TargetCancer Foundation's first grant of $7,500 was provided to the Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer...
United Against Rare Diseases
Did you know that in the US, a disease is considered rare if it affects under 200,000 people? "Rare" doesn't mean much, however, if you or someone you love...
A Remarkable Year in TargetCancer Foundation’s Growth
As 2014 comes to a close, so does our fifth anniversary year. And what an amazing year it has been! A whirlwind to say the least, but we saw the most...